Regarding 2nd-line treatment, significantly longer survival was observed in locally advanced or advanced NSCLC patients receiving nivolumab (CheckMate-017 and CheckMate-057 studies) or atezolizumab (OAK study) compared with docetaxel regardless of PD-L1 expression although it should be noted that greater benefits were observed in patients with higher percentages of TC with PD-L1 expression (22–24). This evidence concerns the gene CD274 and non-small cell lung carcinoma.